Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and DMARD use in the general population, explore racial disparities and describe approaches to begin to address these challenges.
You Might Also Like:
- Pain in RA and OA: ACR Convergence 2020 Preview
- The Great Debate at ACR Convergence 2020: Should Jakinibs Be Used Before Biologics for RA?
- COVID-19, New Research & More: 2 Experts Discuss Scientific Advances in Rheumatology at ACR Convergence 2020
- ACR Convergence 2020 Workshop Covers 2021 Practice Management & Coding Changes